AllianceBernstein
VRDN icon

AllianceBernstein’s Viridian Therapeutics VRDN Stock Holding History

AllianceBernstein’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.3M Sell
1,392,072
-22,109
-2% -$657K 0.01% 646
2025
Q4 		$44M Sell
1,414,181
-445,277
-24% -$12.2M 0.01% 668
2025
Q3 		$40.1M Sell
1,859,458
-84,562
-4% -$1.53M 0.01% 676
2025
Q2 		$27.2M Sell
1,944,020
-77,599
-4% -$1.05M 0.01% 797
2025
Q1 		$27.3M Sell
2,021,619
-265,375
-12% -$4.52M 0.01% 772
2024
Q4 		$43.8M Buy
2,286,994
+84,255
+4% +$1.83M 0.01% 634
2024
Q3 		$50.1M Buy
2,202,739
+204,547
+10% +$3.34M 0.02% 601
2024
Q2 		$26M Buy
1,998,192
+275,373
+16% +$3.81M 0.01% 797
2024
Q1 		$30.2M Sell
1,722,819
-336,645
-16% -$6.53M 0.01% 737
2023
Q4 		$44.9M Buy
2,059,464
+168,466
+9% +$2.66M 0.02% 618
2023
Q3 		$29M Buy
1,890,998
+316,696
+20% +$6.04M 0.01% 733
2023
Q2 		$37.5M Buy
1,574,302
+330,152
+27% +$8.47M 0.02% 660
2023
Q1 		$31.7M Buy
1,244,150
+320,317
+35% +$10.3M 0.01% 698
2022
Q4 		$27M Buy
+923,833
New +$21.3M 0.01% 751
2022
Q3 		– Sell
-50,479
Closed -$584K – 3307
2022
Q2 		$584K Buy
+50,479
New +$678K ﹤0.01% 2613

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein's VRDN Position: Q1 2026 in Review

AllianceBernstein reduced its Viridian Therapeutics (VRDN) stake by 1.6% in Q1 2026, selling an estimated $657K and leaving 1,392,072 shares worth $43.3M. The position accounts for 0.01% of the portfolio, ranked #646.

AllianceBernstein first reported a position in VRDN in Q2 2022 and has held it in 15 quarters since. The position peaked at $50.1M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • AllianceBernstein held 1,392,072 shares of Viridian Therapeutics worth $43.3M as of Q1 2026.
  • AllianceBernstein sold 22,109 Viridian Therapeutics shares in Q1 2026, an estimated $657K.
  • Viridian Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q1 2026, its #646 holding.
  • AllianceBernstein first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • AllianceBernstein's Viridian Therapeutics position peaked at $50.1M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.